LIVOSTIN
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPSPriority Review
Approved
Nov 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIVOSTIN is an ophthalmic suspension approved in 1993 for ocular allergic conditions. The drug is a small-molecule formulation delivered as eye drops. Specific mechanism of action and indications are not detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling a smaller, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LIVOSTIN offers limited career growth due to zero linked job openings and approaching loss of exclusivity. Roles on this product are typically maintenance-focused rather than launch or expansion-oriented, suitable for stabilizing careers but not ideal for rapid advancement.
Brand ManagerField Sales Representative
Worked on LIVOSTIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.